| Catalog | Description | Size | Price (USD) | Qty |
|---|---|---|---|---|
| GBM-2822-50MG | Omeprazole | 50mg | $80.00 | |
| GBM-2822-500MG | Omeprazole | 500mg | $206.00 |
| Bioassays Specification | |
| Bio-Activity | H+/K+ATPase inhibitor |
| Chemical Name | 6-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole |
| Function / Pharmacology | H+,K+-ATPase inhibitor (IC50 = 5.8 μM). Clinically useful antisecretory and antiulcer agent.1 Potent inhibitor of CYP2C19 (Ki=3.1 mM).2 Inhibits swelling-dependent chloride channels.3 Facilitates oral bioavailability of bioactive peptides such as oxytocin by raising stomach pH.4 Displays broad spectrum antiviral activity.5 Enhances efficacy of remdesivir (10-fold).6 |
| CAS# | 73590-58-6 |
| MW | 345.4 |
| Molecular Formula | C17H19N3O3S |
| Solubility | Soluble in DMSO (up to 30 mg/ml) or in Ethanol (up to 5 mg/ml) |
| Supplied | powder |
| Storage as supplied | -20°C |
| Ship temp | Ambient |
| References | 1)Satoh et al. (1989), Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats; J. Pharmacol. Exp. Ther., 248 806 2)Kuzin et al. (2018), Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine; Clin. Pharmacokinet, 57 729 3)Schmarda et al. (2000) The gastric H,K-ATPase blocker Iansoprazole is an inhibitor of chloride channels; Br. J. Pharmacol., 129 598 4)Maejima et al. (2020), Oral oxytocin delivery with proton pump inhibitor pretreatment decreases food intake; Peptides, 128 170312 5)Wantanabe et al. (2020), Selective Targeting of Virus Replication by Proton Pump Inhibitors; Sci. Rep., 10 4003 6)Bojkova et al. (2020), SARS-CoV2 and SARS-CoV differ in their cell tropism and drug sensitivity profiles bioRxiv, epub ahead of print DOI: 10.1101/2020.04.03.024257 |
| Protein Specification | |
| Purity | >98% |
| Bioassays Specification | |
| Bio-Activity | H+/K+ATPase inhibitor |
| Chemical Name | 6-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole |
| Function / Pharmacology | H+,K+-ATPase inhibitor (IC50 = 5.8 μM). Clinically useful antisecretory and antiulcer agent.1 Potent inhibitor of CYP2C19 (Ki=3.1 mM).2 Inhibits swelling-dependent chloride channels.3 Facilitates oral bioavailability of bioactive peptides such as oxytocin by raising stomach pH.4 Displays broad spectrum antiviral activity.5 Enhances efficacy of remdesivir (10-fold).6 |
| CAS# | 73590-58-6 |
| MW | 345.4 |
| Molecular Formula | C17H19N3O3S |
| Solubility | Soluble in DMSO (up to 30 mg/ml) or in Ethanol (up to 5 mg/ml) |
| Supplied | powder |
| Storage as supplied | -20°C |
| Ship temp | Ambient |
| References | 1)Satoh et al. (1989), Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats; J. Pharmacol. Exp. Ther., 248 806 2)Kuzin et al. (2018), Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine; Clin. Pharmacokinet, 57 729 3)Schmarda et al. (2000) The gastric H,K-ATPase blocker Iansoprazole is an inhibitor of chloride channels; Br. J. Pharmacol., 129 598 4)Maejima et al. (2020), Oral oxytocin delivery with proton pump inhibitor pretreatment decreases food intake; Peptides, 128 170312 5)Wantanabe et al. (2020), Selective Targeting of Virus Replication by Proton Pump Inhibitors; Sci. Rep., 10 4003 6)Bojkova et al. (2020), SARS-CoV2 and SARS-CoV differ in their cell tropism and drug sensitivity profiles bioRxiv, epub ahead of print DOI: 10.1101/2020.04.03.024257 |
| Protein Specification | |
| Purity | >98% |
